Valneva (VALN) Competitors $6.15 -0.12 (-1.91%) As of 03:23 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. NAMS, BLTE, HRMY, KNSA, VCEL, DNLI, CGON, VERA, GMTX, and IMCRShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Its Competitors NewAmsterdam Pharma Belite Bio Harmony Biosciences Kiniksa Pharmaceuticals Vericel Denali Therapeutics CG Oncology Vera Therapeutics Gemini Therapeutics Immunocore NewAmsterdam Pharma (NASDAQ:NAMS) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking. Which has more volatility & risk, NAMS or VALN? NewAmsterdam Pharma has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Does the media refer more to NAMS or VALN? In the previous week, NewAmsterdam Pharma had 24 more articles in the media than Valneva. MarketBeat recorded 31 mentions for NewAmsterdam Pharma and 7 mentions for Valneva. NewAmsterdam Pharma's average media sentiment score of 0.53 beat Valneva's score of 0.41 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 10 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend NAMS or VALN? NewAmsterdam Pharma currently has a consensus target price of $43.00, indicating a potential upside of 104.47%. Valneva has a consensus target price of $15.50, indicating a potential upside of 152.03%. Given Valneva's higher probable upside, analysts plainly believe Valneva is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in NAMS or VALN? Valneva received 11 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 91.18% of users gave NewAmsterdam Pharma an outperform vote while only 66.67% of users gave Valneva an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes3191.18% Underperform Votes38.82%ValnevaOutperform Votes4266.67% Underperform Votes2133.33% Do insiders & institutionals believe in NAMS or VALN? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, NAMS or VALN? Valneva has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$47.14M50.09-$176.94M-$1.88-11.19Valneva$186.06M2.76-$109.78M-$1.19-5.17 Is NAMS or VALN more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Valneva's net margin of -4.35%. NewAmsterdam Pharma's return on equity of 0.00% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Valneva -4.35%-3.93%-1.42% SummaryNewAmsterdam Pharma beats Valneva on 11 of the 17 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$514.36M$3.12B$5.61B$8.62BDividend YieldN/A1.57%5.28%4.18%P/E Ratio-47.3132.8927.2619.97Price / Sales2.76466.19412.06157.64Price / CashN/A168.6838.2534.64Price / Book3.083.417.064.69Net Income-$109.78M-$72.35M$3.24B$248.14M7 Day Performance-3.15%6.75%2.56%2.39%1 Month Performance-4.65%17.19%8.75%6.06%1 Year Performance-26.61%-17.58%31.30%13.57% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.6126 of 5 stars$6.15-1.9%$15.50+152.0%-24.1%$514.36M$186.06M-47.31700Short Interest ↓NAMSNewAmsterdam Pharma2.9774 of 5 stars$18.93+4.5%$43.00+127.2%+3.2%$2.13B$47.14M-10.074Trending NewsAnalyst ForecastAnalyst RevisionBLTEBelite Bio2.3014 of 5 stars$65.02+0.2%$96.67+48.7%+25.2%$2.07BN/A-58.5810Short Interest ↑Analyst RevisionHRMYHarmony Biosciences4.7815 of 5 stars$35.56+3.1%$53.00+49.0%+18.4%$2.04B$744.85M16.85200Positive NewsShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals3.2514 of 5 stars$27.92+2.0%$38.80+39.0%+61.1%$2.04B$481.17M-199.41220Trending NewsInsider TradeVCELVericel2.6548 of 5 stars$40.46-2.0%$61.14+51.1%+2.0%$2.04B$238.54M674.45300Positive NewsHigh Trading VolumeDNLIDenali Therapeutics4.3475 of 5 stars$13.96+5.4%$33.71+141.5%-29.7%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionHigh Trading VolumeCGONCG Oncology2.5014 of 5 stars$26.59+3.8%$58.22+119.0%-25.6%$2.03B$662K-17.6161Positive NewsAnalyst RevisionVERAVera Therapeutics2.899 of 5 stars$31.74+67.5%$65.00+104.8%-42.5%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+33.6%$2.02BN/A-46.6830High Trading VolumeIMCRImmunocore3.0554 of 5 stars$38.65+5.6%$58.89+52.4%-13.5%$1.94B$333.58M-40.68320Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies NAMS Alternatives BLTE Alternatives HRMY Alternatives KNSA Alternatives VCEL Alternatives DNLI Alternatives CGON Alternatives VERA Alternatives GMTX Alternatives IMCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VALN Stock Free VALN Stock Alerts